Letermovir vs Valganciclovir for CMV Prevention After Kidney Transplant
Treatments studied
Part of Blood & lymphatic, Infections clinical trials.
This study compares two antiviral medications to prevent CMV (a common virus that can cause problems after kidney transplant) in people who had the virus before their transplant. The goal is to see which medicine works better and is safer for preventing CMV disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old
- You received a kidney transplant and tested positive for CMV antibodies before or at transplant
- You can take medications by mouth
- You do not have uncontrolled infections or serious liver disease (for letermovir arm)
- You have not had CMV disease or taken CMV medications in the past week
- You are not pregnant, breastfeeding, or planning to become pregnant during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests if doctors can safely stop the anti-CMV drug letermovir earlier in stem cell transplant patients who have recovered their immune system. It focuses on patients who are at high risk for CMV but currently have no active infection.
This Phase 2 trial tests whether the medicine letermovir can prevent a common viral infection (CMV) after a new heart transplant. It may help reduce CMV infection or illness in people who are at moderate to high CMV risk.
This trial compares two antiviral drugs, valganciclovir and letermovir, to see which works better at preventing CMV infection after a heart transplant. If you've had a heart transplant and haven't started preventive treatment yet, this study may be for you.
This trial tests adding a drug called letermovir to standard antiviral therapy for lung transplant patients with CMV infection. The goal is to see if the combination helps clear the virus faster and more effectively.
This trial tests whether taking letermovir for a longer time can prevent CMV (a common virus) from reactivating in adults with certain risk factors after a donor stem cell transplant. If you're preparing for your first transplant and have a high-risk donor or conditioning, this study may be an option.
This trial tests whether the drug letermovir can prevent cytomegalovirus (CMV) infection in people who have had a stem cell transplant. It is for adults who are CMV-positive and have not yet had a CMV infection.
Hear when a new CMV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.